<p>The U.S. Food and Drug Administration (FDA) has approved Gilead Sciences' antiviral drug for biannual use to prevent HIV. The company and some experts have stated that this is a milestone that could help the world get closer to ending the decades-long HIV epidemic. However, the launch of the injectable lenacapavir faces a series of potential threats, including the Trump administration's proposal to cut federal funding for HIV prevention efforts</p>

GILD

<p>The U.S. Food and Drug Administration (FDA) has approved Gilead Sciences' antiviral drug lenacapavir for HIV prevention twice a year, with experts calling this a milestone that could help end the HIV epidemic. However, the drug's market launch faces the threat of funding cuts for HIV prevention proposed by the Trump administration</p>

The U.S. Food and Drug Administration (FDA) has approved Gilead's biannual HIV prevention injection, providing a powerful and convenient new option